Table 1.
Characteristics of the 83 participants in this randomized controlled trial.
| Characteristics* | All n=83 | By Study Arm | ||
|---|---|---|---|---|
| STRIVE-LT n=58 (70%) | Control n=25 (30%) | |||
| Female | 43% | 50% | 28% | |
| Age, years | 61 (55–65) | 62 (56–66) | 61 (42–72) | |
| Race/Ethnicity | White | 83% | 96% | 68% |
| Black | 10% | 0% | 14% | |
| Asian | 6% | 4% | 7% | |
| Other | 2% | 2% | 2% | |
| Height, cm | 170 (165–178) | 170 (163–175) | 173 (168–180) | |
| Body mass index, kg/m2 | 28 (26–33) | 28 (26–33) | 28 (26–33) | |
| Etiology of liver disease | Chronic hepatitis C | 37% | 36% | 40% |
| Alcohol | 21% | 19% | 24% | |
| Non-alcoholic fatty liver disease | 12% | 10% | 16% | |
| Autoimmune/cholestatic | 18% | 21% | 12% | |
| Other | 12% | 14% | 8% | |
| Hepatocellular carcinoma | 39% | 36% | 44% | |
| Hypertension | 48% | 48% | 48% | |
| Diabetes | 33% | 36% | 24% | |
| Coronary artery disease | 5% | 5% | 4% | |
| Baseline MELDNa | 14 (11–19) | 12 (6–32) | 13 (6–23) | |
| MELDNa at 12 weeks | 15 (11–17) | 15 (6–24) | 15 (11–17) | |
| Albumin, g/dL | 3.3 (2.8–3.7) | 3.4 (2.8–3.8) | 3.0 (2.8–3.6) | |
| Ascites | 22% | 21% | 25% | |
| Hepatic encephalopathy | 24% | 19% | 36% | |
| Child Pugh B/C | 54% | 53% | 54% | |
*
Median (IQR) or %